Marketresearchnews

Saturday, 5 June 2021

Global CBCT Dental Imaging Market 2020 Industry Key Players, Trends, Sales, Supply, Demand, Analysis & Forecast By 2027

The Global CBCT Dental Imaging Market is expected to register a CAGR of 9.8%and is anticipated to reach USD 817.5 Million by 2023. Dental Cone Beam Computed Tomography (CBCT) is a distinctive type of x-ray machine used in circumstances where regular dental or facial x-rays are not enough. This type of computed tomography scanner uses a special type of technology to produce three dimensional (3D) images of oral structures, soft tissues, nerve paths and bone in the craniofacial region in a single scan.

The growing use of CBCT in orthodontic diagnosis and treatment, increasing the use of CBCT imaging in cosmetic dentistry treatments, and rising adoption of CBCT by the healthcare professionals are the major drivers propelling market growth. However, the lack of awareness for the use of advanced technologies and risk of ionizing radiations for children and teens may hinder the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2203

Market Dynamics

Many institutes are using CBCT imaging technology is coupled with 3D clinical photography and accurate predictive altering for the precise diagnosis, planning, and treatment of orthodontics, and facial deformities and dental and facial implant surgeries. Institutes such as Inland Institute Oral & Maxillofacial Surgery are using full-craniofacial cone-beam CT (computed tomography) technology for highly accurate 3D radiographic images which will help in diagnosing, and planning and treating oral and maxillofacial surgery. The increasing use of CBCT for oral and maxillofacial surgery is driving the market for global CBCT dental imaging market. Additionally, increasing the use of CBCT in orthodontic diagnosis and treatment and increasing adoption of CBCT by healthcare professionals is likely to support market growth. On the other hand, lack of awareness for the use of advanced technologies and risk of ionizing radiations for children and teens are anticipated to hamper the market growth.

Segmentation

The global CBCT dental imaging market has been segmented into type of detector, application, and end user. Based on detectors, the dental CBCT imaging market has been classified as flat panel detectors and image intensifiers. The global CBCT dental imaging market, by application, has been ranked as dental implants, orthodontics, endodontic, and others. By end user, the market has been categorized as hospitals and dental clinics, academic and research institutes, and others. The hospitals and dental clinics segment accounted for a market value of USD 262 million in 2015.

Key Players

The prominent players in the global CBCT dental imaging market are Carestream Health (US), Dentsply Sirona (US), FONA Dental, SRO (Slovakia), Gendex (US), Imaging Sciences International, LLC (US), J.MORITA MFG. CORP. (Japan), KaVo Dental GmbH (Germany), New Tom (Italy), Planmeca OY (Finland), Prexion (US), Sinclair Dental/Dentaire (Canada), SOREDEX (Finland), and Vatech Networks (South Korea)

Some of the key strategies followed by the players operating in the global CBCT dental imaging market were innovation, product development, acquisition, and expansion.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cbct-dental-imaging-market-2203

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Egg Allergy Market Trends Analysis Research Report 2020-2027

The Global Egg Allergy Market is expected to register a CAGR of 7.10%and is anticipated to reach USD 2304.3 Million by 2023. Egg allergies are the most common food allergies. Symptoms of egg allergy can occur immediately or within a few minutes or a few hours. Egg allergy can affect infants as well as adults. The adverse effects of egg allergy can vary from hives or rashes to a severe allergic reaction known as anaphylaxis. Egg allergy happens when there is an overreaction to eggs by the immune system. The immune system identifies egg proteins as harmful and triggers an allergic reaction.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4734

The increasing prevalence of egg allergy and improved allergy diagnosis are the major drivers propelling market growth. However, the lack of awareness in developing countries and high cost constrain the growth of the market.

Market Dynamics

The continued growth in several egg allergy patients is responsible for the increasing demand for required diagnostic tests and medication such as epinephrine autoinjectors, and ultimately, it is propelling the growth of the market. For instance, according to the report published by, McGill University in 2016, egg allergy is common in infants and young children and affects 1 to 2% of the preschool children. Additionally, improved allergy diagnosis is likely to support market growth. On the other hand, the lack of awareness in developing countries and high cost is anticipated to hamper the market growth.

Segmentation

The global egg allergy market has been segmented into age type, diagnosis & treatment, and end user. By age type, the market has been segmented into children and adults. The global egg allergy market has two primary sides—diagnosis & treatment. The global egg allergy market, by diagnosis, has been segmented into skin test, blood test, food challenge, and others. The global egg allergy market, by treatment, has been segmented into medication and oral immunotherapy. By end-user, the market has been segmented into hospitals and clinics, diagnostic centers, research institutes, and others. The hospitals and clinics segment accounted for a market value of USD 729.2 million in 2017.

Key Players

The prominent players in the global egg allergy market are Sanofi SA (France), Genentech, Inc. (the US), Quest Diagnostics (US), ImmuneTech (US), HYCOR Biomedical (US), Kaleo, Inc. (the US), Alletess Medical Laboratory (US), Creative Diagnostics (US), Imutest Ltd (UK), Mylan NV (US), and Impax Laboratories (US).

Some of the key strategies followed by the players operating in the global egg allergy market were innovation, product development, acquisition, and expansion.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/egg-allergy-market-4734

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Tissue Microarray Market Growth Insight Analysis 2020-2027

The Global Tissue Microarray Market is expected to register a CAGR of 10.54% and is anticipated to reach USD 10,914.54 million by 2023. Tissue microarrays are paraffin blocks that are created by separating cylindrical tissue cores from different paraffin donor blocks and re-embedding these into a microarray at defined array coordinates. With the help of tissue microarray, up to at least 1000 tissue samples can be arrayed into a single paraffin piece. It allows simultaneous analysis of molecules present in DNA, mRNA, and protein levels under identical, standardized conditions on a single glass slide. This adaptable strategy, in which data analysis is automated, facilitates retrospective and prospective human tissue studies.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1213

The increasing application in drug discovery, increasing prevalence of cancer, growing advancements in biotechnology and pharmaceutical companies, and rising demand for cost-effective and accurate diagnostic methods are the major drivers propelling market growth. However, tissue microarray may not be fruitful for heterogeneous cancers, which is likely to constrain the growth of the market.

Market Dynamics

The prevalence of cancer is one of the crucial factors that drive the growth of the tissue microarray market. According to the American Cancer Society, in 2017, nearly 13% of all cancers diagnosed in adults aged 20. It further stated that rates of liver cancer, thyroid cancer, and melanoma are increasing from last few years. According to US Breast Cancer Statistics, about 1 in 8 US women (about 12%) will develop invasive breast cancer throughout their lifetime. In 2017, an estimated 252,710 new cases of invasive breast cancer were expected to be diagnosed in women in the US, along with 63,410 new cases of non-invasive (in-situ) breast cancer.

Moreover, increasing advancements in biotechnology and pharmaceutical companies and growing demand for cost-effective and accurate diagnostic methods have fueled the growth of the market. On the other hand, tissue microarray is that it may not be fruitful for heterogeneous cancers anticipated to hamper the market growth.

Segmentation

The global tissue microarray market has been divided into the procedure, technology, application, and end user. By procedure, the market has been segregated into immunohistochemistry, fluorescent in-situ hybridization, and frozen tissue array. Based on technology, the market has been segmented into DNA microarray, polymerase chain reaction (PCR), next-generation sequencing, northern blotting, and western blotting. Based on the application, the market has been bifurcated into oncology, gene expression profiling, SNP detection, double-stranded B-DNA microarrays, comparative genomic hybridization, and sequencing bioinformatics. By end-user, the market has been classified as pharmaceutical and biotechnological companies and research organization. The research organization segment accounted for a market value of USD 1876.02 million in 2016.

Key Players

The prominent players in the global tissue microarray market are Agilent Technologies, Illumina, Inc., Protein Biotechnologies Inc., Asterand Bioscience, Pantomics Inc., Applied Microarrays, Arrayit, Phalanx Biotech, QIAGEN, Takara Bio, Perkin Elmer, and Merck Sharp & Dohme Corp.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/tissue-microarray-market-1213

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Automated Hospital Beds Market Growth Insight Analysis 2020-2027

The Global Automated Hospital Beds Market is expected to register a CAGR of 5.97% and is anticipated to reach USD 2,553.4 million by 2023.

Automated hospital beds are specially designed for hospitalized patients in need of some form of health care services. These hospitals beds have special features both for the comfort and well-being of the patient and for the convenience of health care workers. Most common features of automated hospital beds are automated adjustable height for the entire bed including the head and the feet, adjustable side rails, and electronic buttons to operate both the bed and other nearby electronic devices.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4250

The increase in the number of various acute and chronic disorders, rising geriatric population, increased number of obese people, continuous development in the designs of the hospital beds for the betterment and more comfort of the patients, and rising healthcare expenditure are the major drivers propelling market growth. However, the high cost of automated hospital beds and expensive maintenance of automated hospital beds are hampering the growth of the market.

Market Dynamics

The rise in the incidence rates of chronic disorders is expected to drive the growth of the market. According to the American Autoimmune Related Diseases Association, in 2017, approximately 50 million Americans were suffering from autoimmune diseases, and more than USD 591 million was spent on research and development of autoimmune disorders. Moreover, the increasing geriatric population, increased number of obese people are also likely to support market growth. On the other hand, the high cost of automated beds and the expensive maintenance of hospital beds is anticipated to hamper the market growth.

Segmentation

The global automated hospital beds market has been segmented into type, technology, type of treatment, usage and end user. By type, the market has been segmented into semi-automatic hospital beds and fully automatic hospital beds. Technology segment has been divided into basic automated hospital beds and smart, automated hospital beds. Based on the type of treatment, the market has been segmented into critical care, acute care, and long-term care. Based on usage, the market has been segmented into general-purpose, intensive care, delivery/birthing, bariatric, pediatric, psychiatric care, pressure relief, and others. By end-user, the market has been segmented hospitals & clinics reproductive care centers, dentistry, home care, and others. The hospitals & clinics segment accounted for a market value of USD 627.4 million in 2016.

Key Players

The prominent players in the global automated hospital beds market are ArjoHuntleigh, Gendron Inc, Hill-Rom Holdings, Invacare Corporation, Linet spol. SRO, Medline Industries, Inc., Stryker Corporation, Paramount Bed Holdings Co., Ltd., and Others.

Regional Analysis

The global automated hospital beds market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The European region is estimated to dominate the global automated hospital beds market during the forecast period. This is attributed to the continuous innovation and new product development, moreover, to rise in prevalence of life-threatening diseases, increasing healthcare expenditure and increasing technological advances play a vital role in the growth of the regional market. Furthermore, in an automated hospital beds market, Europe accounted for a market share of 36.0% in 2016. The North America market for automated hospital beds is expected to be the second-largest during the forecast period. Factors such as stable economic conditions and continuously developing technologies and significant investments by hospitals to upgrade their equipment’s including beds is expected to boost the growth of the market in this region. For instance, According to WHO, the North American population is projected to grow by 42% from 2000 to 2050, and so it is imperative that the supply of health care maintains pace with the increased demand

Additionally, the companies operating in the market are mainly concentrating on strategic collaborations and mergers and acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to the increasing incidence of chronic diseases, the government encouragement in the healthcare sector, and growing the working population in the healthcare industry. Furthermore, the market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/automated-hospital-beds-market-4250

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Capillary Blood Collection Devices Market Current Trends, SWOT Analysis, Strategies, Industry Challenges, Business Overview and Forecast Research Study 2027

Global Capillary Blood Collection Devices Market is expected to register a CAGR of 10.3%and is anticipated to reach USD 778.38 Million by 2027. Capillary blood collection devices are well-known technology within blood collection devices. Formerly, these capillary blood collection devices were used for diagnosis of the chronic disease, but nowadays, these capillary devices have wide-range applications. Despite the saturation in developed countries, the market for capillary blood collection devices in healthcare and life science is anticipated to grow.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4213

The increasing prevalence of diabetes, leading to high demand for lancets, favorable medical device regulation, and increasing geriatric population are the major drivers propelling the market growth. However, the risk associated with capillary blood assortment techniques and blood contaminations constrains the growth of the market.

Market Dynamics

The increase in the geriatric population expected to drive the growth of the market. For instance, according to the population reference bureau, the number of Americans aging 65 and older is projected to be more than double from 46 million in 2015 to over 98 million by 2060. Due to the damage or weakening of blood vessels in the geriatric population, capillary blood sampling devices are used so that minimal damage occurs.

Moreover, increasing prevalence of diabetes and growing demand for lancets has fueled the growth of the market. Additionally, favorable medical device regulations are likely to support market growth. On the other hand, the risks related to contamination due to the capillary blood assortment techniques is anticipated to hamper the market growth.

Segmentation

The global capillary blood collection devices market has been segmented into material, type of devices, and end-user. By material, the market has been segregated into plastic, glass, stainless steel, and others.

Based on the type of devices, the market has been divided into blood collecting tubes and collectors, lancets, warming devices, and others.

By end-user, the market has been classified as hospitals & clinics, diagnostic centers and pathology laboratories, home diagnostics, and others. The hospitals & clinics segment accounted for a market value of USD 190.36 million in 2019.

Key Players

The prominent players in the global Capillary Blood Collection Devices market are F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories, Novo Nordisk AS, Becton Dickinson and Company, Medtronic PLC, B. Braun Melsungen AG, Thermo Fisher Scientific Inc., Terumo Corporation, Ypsomed Holding AG, HTL-STREFA SA, Sarstedt AG & Co, Owen Mumford Ltd, Greiner Bio-One, Improve Medical, and Chengdu Rich Science Industry Co., Ltd.

Some of the key strategies followed by the players operating in the global capillary blood collection devices market were innovation, product development, acquisition, and expansion.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/capillary-blood-collection-devices-market-4213

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Medical Automation Market – Functional Survey 2027

The Global Medical Automation Market is expected to register a CAGR of 7.0% and is anticipated to reach USD 42,284.6 million by 2023. Automation is defined as the use of control systems and information technologies to reduce the need for human work in the production of goods and services. In recent years, technological advancements have been incorporated into the medical sector, which drives the growth of the medical automation market.

The increasing prevalence of chronic diseases like cancer, diabetes, and others, growing pharmaceutical & biotechnology sector and increasing demand for robotic surgery and rising healthcare expenditure are the major drivers propelling market growth. However, the high cost of automation and risks associated with robotic surgery, followed by the necessity of physician training are expected to constrain the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5184

Market Dynamics

The increasing prevalence of chronic diseases like cancer, diabetes, and others, along with the growing pharmaceutical & biotechnology sector and rising demand for robotic surgery are the major drivers propelling market growth. For instance, according to a report published by the National Cancer Institute in 2016, approximately 1,685,210 new cases of cancer were diagnosed in the US. Moreover, rising healthcare expenditure is also projected to boost market growth. However, the high cost of automation and risks associated with robotic surgery, followed by the necessity of physician training are expected to constrain the growth of the market.

Segmentation

The global medical automation market has been segmented into type, and end user. By type, the market has been divided into diagnostics & monitoring automation, therapeutic automation, lab & pharmacy automation, and medical logistics & training. Diagnostic & monitoring automation is further segregated into automated imaging, point-of-care testing (POCT), and automated image analysis. Therapeutic automation is further bifurcated into non-surgical automation and surgical automation. Medical logistics & training is also classified as logistics automation and trainers. By end-user, the market has been categorized as hospitals & diagnostic centers, pharmacies, research labs & institutes, and others. The hospitals & diagnostic centers segment accounted for a market value of USD 8,554.7 million in 2016.

Key Players

The prominent players in the global medical automation market are Koninklijke Philips NV (Netherlands), Siemens AG (US), General Electric (US), Medtronic (US), Stryker (US), Danaher (US), and Accuray Incorporated (US).

Some of the key strategies followed by the players operating in the global medical automation market were innovation, product development, acquisition, and expansion.

Regional Analysis

The global medical automation market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is estimated to dominate the global medical automation market during the forecast period due to increasing demands for medical automation in the presence of the increasing prevalence of diseases like cancer, diabetes, among others.

Moreover, growing biotech and biopharmaceutical sector within the region drives the market during the forecast period. The European market for medical automation is expected to be the second-largest during the forecast period. The increasing per capita healthcare expenditure and rising number of robotic surgical procedures are the drivers fueling the market growth.

Asia-Pacific is estimated to be the fastest-growing market due to the growing biotech and biopharmaceutical factor, increasing patient population, and rising healthcare expenditures along with the increasing demands for the robotic surgery. Moreover, in the Asia-Pacific, South Korea accounted for a market share of 12% in 2016. Furthermore, the market in the Middle East & Africa is expected to witness steady growth due to the presence of the low per capita income and stringent government policies, especially within the African region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/medical-automation-market-5184

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Friday, 4 June 2021

Companion Diagnostics for Oncology Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Market Overview

Global Companion Diagnostics for Oncology Market forecast 2019 was valued at USD 1,603.16 Million and is expected to register a CAGR of 22.57% during the forecast period of 2020 to 2027.

Companion diagnostic (CDx) is a diagnostic testing kit majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. With the rise in cancer prevalence, coupled with increasing strategic initiatives, there has been a huge demand for companion diagnostics in the oncology area. The growing prevalence of cancer across the globe is increasing the preference for targeted therapy, which is affecting the demand for CDx tests. According to Cancer Research UK, there were 17 million new cases of cancer across the world in 2018, in which lung and breast cancer accounted for the largest share, followed by colorectal and prostate cancer.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/10422

Market Dynamics

The key factors driving the market growth are increasing R&D and drug-diagnostic co-development, growing preference for personalized medicine, increasing global incidence of cancer, and increasing product approvals by major players. However, the lack of reimbursement in developing regions may hamper the market growth. The entry of market players in evolving economies creates an opportunity to drive the companion diagnostics for oncology market.

Major market players are focusing on various growth strategies such as product launches, product advancements, and business expansions to cater to the growing need for personalized medicine. These product launches and business expansion drive the growth of the companion diagnostics for oncology market. For instance, in March 2020, Thermo Fisher signed a strategic agreement with Janssen Services to co-develop a companion diagnostic product related to oncology, which will support clinical trial enrollment globally. In March 2019, Roche launched the Ventana PD-L1 (SP142) Assay in Europe as the first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq. Similarly, in March 2019, Roche received the US FDA approval for its Ventana PD-L1 (SP142) assay approved as the first companion diagnostic to identify triple-negative breast cancer patients eligible for the treatment with Tecentriq in combination with Abraxane. Furthermore, in April 2018, Illumina entered a collaboration with Bristol Myers Squibb Company to utilize Illumina’s next-generation sequencing technology to develop and globally commercialize companion diagnostics for Bristol-Myers Squibb Company’s oncology immunotherapies, and the growing prevalence of cancer across the globe is increasing the preference for targeted therapy which is affecting the demand for CDx tests.

Segmentation

Global Companion Diagnostics for Oncology Market has been divided based on Products & Services, Technology, Indication, and End User.

Global Companion Diagnostics for Oncology Market, on the basis of product & service, has been segmented into assays, kits & reagents and software & services. The assays, kits, & reagents segment is expected to be the largest of 62.1% in 2019 and is projected to be the fastest market owing to their continuous requirement by end users.

Based on technology, the global companion diagnostics for oncology market is segmented into polymerase chain reaction (PCR) and next-generation sequencing (NGS). By technology, polymerase chain reaction (PCR) held a larger market share of 53.8% in 2019, whereas the NGS segment accounted for a CAGR of 25.05% during the forecast period of 2020 to 2027.

The global companion diagnostics for oncology market, on the basis of indication, has been segmented into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others. The breast cancer segment accounted for the largest market share in 2019, owing to the huge population suffering from cancer across the globe.

The global companion diagnostics for oncology market, on the basis of end user, is segmented into pharmaceutical & biopharmaceutical companies, laboratories, contract research organizations, and others. The pharmaceutical & biopharmaceutical companies segment accounted for the largest share of 38.2% in 2019, owing to the rising adoption of companion diagnostics for oncology techniques among researchers and clinicians.

Regional Analysis

Global Companion Diagnostics for Oncology Market based on region is segmented into four main regions, including the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas accounted for the major share in 2019, whereas Asia-Pacific is projected to be the fastest-growing region during the forecast period.

In the global companion diagnostics for oncology market, the Americas held the largest share of 37.3% in 2019. The market growth in the Americas is due to the high prevalence rate of cancer and other chronic disorders and rising healthcare expenditure. According, to the National Institutes of Health, it was estimated that 1,735,350 new cases of cancer were diagnosed in the US in 2018. Additionally, the American Cancer Society estimated that 1.8 million new cancer cases would be diagnosed in 2020 in the US.

Europe acquired the second-largest market share in 2019. The market is expected to register a sturdy growth rate during the forecast period due to the presence of a large number of companies, growing research and development activities to develop targeted drug therapy for a cancer patient, and rising per capita income increases the preference for personalized medicine. According to the European Journal of Cancer, there were around 3.9 million new cases and 1.9 million deaths from cancer in Europe in 2018. The increasing cancer population supports market growth in this region.

Asia-Pacific is anticipated to be the fastest-growing regional market during the forecast period. The rapid growth of the Asia-Pacific regional market is due to the rising number of cancer patients and the growing presence of market players. According to the Global Cancer Observatory, around 1,157,294 cases of cancer were reported in India in 2018. Additionally, growing research funding, rising investments by pharmaceutical and biotechnology companies and growing awareness about personalized therapeutics in several APAC countries are expected to drive the growth of the Asia-Pacific market.

The Middle East & Africa accounted for the least value of USD 82.64 million in 2019. The companion diagnostics for oncology market in countries such as Kuwait, the UAE, and Saudi Arabia are likely to show steady growth due to increasing cancer cases, rising drug discovery, and increasing preference for personalized medicines. Also, the growing number of hospitals and research laboratories and increasing investment by healthcare companies in this region drives the growth of the market in Middle East & Africa.

Key Players

The Prominent Players in the Global Companion Diagnostics for Oncology Market are Agilent Technologies Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, BioMérieux SA, Foundation Medicine, Archer Dx, Qiagen, Thermo Fisher Scientific Inc., Amoy Dx, and Abbott.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/companion-diagnostics-oncology-market-10422